NCT04836663 - A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 23, 2021

Primary Completion Date

September 30, 2022

Study Completion Date

December 30, 2022

Conditions

Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer

Interventions

DRUG

TQ-B3525 tablet

TQ-B3525 tablet administered orally once a day. Each cycle is 28 days.

Trial Locations (5)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

NOT_YET_RECRUITING

Gynecology Hospital of Fudan University, Shanghai

NOT_YET_RECRUITING

The First People's Hospital of Changzhou, Changzhou

NOT_YET_RECRUITING

Sir Run Run Shaw Hospital Medical School Zhejiang University, Hangzhou

NOT_YET_RECRUITING

Nanjing Drum Tower Hospital, Nanjing